NEXGEL (NASDAQ:NXGL) Shares Down 6.4%

NEXGEL, Inc. (NASDAQ:NXGLGet Free Report) was down 6.4% on Thursday . The company traded as low as $2.32 and last traded at $2.34. Approximately 9,096 shares traded hands during trading, a decline of 79% from the average daily volume of 44,255 shares. The stock had previously closed at $2.50.

NEXGEL Trading Down 6.4 %

The stock has a market capitalization of $13.34 million, a P/E ratio of -3.90 and a beta of 0.39. The company has a current ratio of 4.01, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $2.22 and a 200 day moving average price of $1.95.

NEXGEL (NASDAQ:NXGLGet Free Report) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.12) earnings per share for the quarter. The firm had revenue of $1.17 million for the quarter. NEXGEL had a negative net margin of 117.54% and a negative return on equity of 45.19%.

Institutional Investors Weigh In On NEXGEL

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in shares of NEXGEL during the second quarter worth about $34,000. Geode Capital Management LLC acquired a new stake in shares of NEXGEL in the 2nd quarter worth approximately $98,000. Finally, Citadel Advisors LLC acquired a new stake in shares of NEXGEL in the 2nd quarter worth approximately $36,000. Institutional investors and hedge funds own 2.78% of the company’s stock.

NEXGEL Company Profile

(Get Free Report)

NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.

Further Reading

Receive News & Ratings for NEXGEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NEXGEL and related companies with's FREE daily email newsletter.